Medtronic’s Newest Generation Evolut FX+ System Nabs FDA Nod

Medtronic today announced that FDA has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The system is the latest iteration of Evolut FX+ which maintains the performance benefits of the legacy version which is designed to facilitate coronary access while also incorporating new advancements.